Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?

Highlights

• Intrathecal autologous bone marrow mononuclear cell (BMMNC) therapy combined with education improved core ASD symptoms and adaptive functioning compared to education alone.
• Significant reductions in the severity of ASD were observed at 12 months, with greater improvements in social, adaptive, and daily living skills.
• The study adds to emerging evidence for cell-based therapies as adjuncts to standard behavioral interventions in pediatric ASD.

Study Background and Disease Burden